I think there is room for a little disappointment that there is...

I think there is room for a little disappointment that there is not more substance to the announcement;
the MSF clinical study is nothing to get excited about as it will probably become redundant as soon as FDA approves - as I'm sure they will.
However, that MSF are named, and have declared support is excellent. They already know ResApp works for them.
All is good.
Very good news; don't think the trading halt was warranted.